 Spectrum --
July 2008
 Introduction:
Panic disorder (PD) affects a large number of people and has
a large diagnosed and drug-treated population. Nonetheless, the pipeline for agents
to treat PD remains small, eclipsed by the development of agents for other
anxiety disorders. This dearth opens a clear opportunity for an emerging agent
that can offer superior efficacy over the available options.
Get the Answers You Need to Shape Your Strategy:
 PD can be highly debilitating, with the associated anxiety
causing those with this disease to significantly limit their activities. How
many people in the seven major markets we cover (the United States, France,
Germany, Italy, Spain, the United Kingdom, and Japan) have PD? What brain
structures and neurotransmitters have been implicated in the development of PD?
How is the disease diagnosed?
A variety of drug classes are used to treat PD. What are
the most popular therapies for the treatment of PD? Does approval for the
treatment of the disease increase the likelihood it will be prescribed?
Few agents are being developed for the treatment of PD. Why
are drug developers choosing to develop agents for anxiety orders other than
PD? What agents are currently in the pipeline for PD, and are they likely to
replace any existing agents? What changes can be expected in the PD market over
the next five years?
Scope:
Overview of PD: disease description, diagnosis,
pathophysiology, and prevalence.
Current therapies: selective serotonin reuptake
inhibitors, serotonin and norepinephrine reuptake inhibitors, and
benzodiazepines.
Emerging therapies: challenges to developing agents for
PD, Sepracor’s SEP-225441, and Alexza Pharmaceuticals’ AZ-002.
PD market: 2007 statistics, outlook for emerging
agents.
|
